Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Humacyte, Inc. (HUMA : NSDQ)

• Company Description    Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C. Number of Employees: 184

• Price / Volume Information    Yesterday's Closing Price: $0.41 Daily Weekly Monthly 20 Day Moving Average: 6,576,901 shares Shares Outstanding: 277.80 (millions) Market Capitalization: $114.23 (millions) Beta: 2.44 52 Week High: $1.78 52 Week Low: $0.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -27.31% -27.79% 12 Week -34.17% -37.91% Year To Date -57.19% -62.22%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2525 EAST NORTH CAROLINA HIGHWAY 54 - DURHAM,NC 27713 USA ph: 919-313-9633 fax: - investors@humacyte.com http://www.humacyte.com

• General Corporate Information    Officers Laura E. Niklason - President and Chief Executive Officer Dale A. Sander - Chief Financial Officer Kathleen Sebelius - Director John Bamforth - Director Emery N. Brown - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44486Q103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 277.80 Most Recent Split Date: (:1) Beta: 2.44 Market Capitalization: $114.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.65 Price/Cash Flow: - Price / Sales: 53.86 EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: -77.78% Sales Growth vs. Year Ago Period: 34.88% vs. Previous Quarter: -17.98% ROE 09/30/26 - - 06/30/26 - -983.32 03/31/26 - -2,914.18 ROA 09/30/26 - - 06/30/26 - -88.84 03/31/26 - -89.45 Current Ratio 09/30/26 - - 06/30/26 - 6.21 03/31/26 - 3.93 Quick Ratio 09/30/26 - - 06/30/26 - 5.74 03/31/26 - 3.32 Operating Margin 09/30/26 - - 06/30/26 - -4,780.20 03/31/26 - -5,071.63 Net Margin 09/30/26 - - 06/30/26 - -4,556.29 03/31/26 - -4,836.06 Pre-Tax Margin 09/30/26 - - 06/30/26 - -4,560.82 03/31/26 - -4,840.82 Book Value 09/30/26 - - 06/30/26 - 0.11 03/31/26 - 0.05 Inventory Turnover 09/30/26 - - 06/30/26 - 1.03 03/31/26 - 0.88 Debt-to-Equity 09/30/26 - - 06/30/26 - 2.07 03/31/26 - 5.46 Debt-to-Capital 09/30/26 - - 06/30/26 - 67.41 03/31/26 - 84.52

Powered by Zacks Investment Research ©